RxDoctor Payments DataLook up a doctor →

Martin Belkin, DO

Neurology · Farmington Hills, MINPI 1861462129

Payments from drug & device makers

$5,762,105in general payments, 2019–2025

Across 1,834 payments — averaging $3141.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1.6M
  • AbbVie$1M
  • Novartis$831K
  • TG Therapeutics, Inc.$450K
  • Sanofi$372K
  • F. Hoffmann-la Roche AG$353K
  • plus $1.1M from 34 others

What the payments were for

  • Consulting fees$99,69014%
  • Speaking & faculty fees$565,95580%
  • Travel & lodging$23,7063%
  • Food & beverage$22,2263%
  • Education$1160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,762,105 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$7,947,521
Medicare patients
730
Services billed
464,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a109$867,846
Avonex Pen (4 Pack)Interferon Beta-1a82$664,963
Kesimpta PenOfatumumab43$424,942
CopaxoneGlatiramer Acetate47$335,590
AubagioTeriflunomide28$320,725
AmpyraDalfampridine44$252,762
VumerityDiroximel Fumarate25$213,587
Teriflunomide93$212,054
TysabriNatalizumab16$153,110
GilenyaFingolimod Hcl15$141,228
TecfideraDimethyl Fumarate13$120,816
KeppraLevetiracetam26$117,612
Dalfampridine ErDalfampridine192$95,251
LamictalLamotrigine26$72,270
GlatopaGlatiramer Acetate27$63,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Vumerity, Tysabri, Tecfidera$1,562,070$1,355,359163 claims
Teva Pharmaceuticals USA, Inc.Copaxone$6,894$335,59047 claims
SanofiAubagio$372,482$320,72528 claims
Acorda Therapeutics, IncAmpyra$41$252,76244 claims
NovartisGilenya$831,360$141,22815 claims
UCB, Inc.Vimpat, Briviact$99$80,27441 claims
PfizerNurtec Odt$208$55,62031 claims
Sunovion Pharmaceuticals Inc.Aptiom$51$55,48927 claims
Avanir Pharmaceuticals, Inc.Nuedexta$58$21,29213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.

Other neurology in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →